1,597 material Form 8-K filings that 1,208 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Matador Resources Company priced a private offering of $750 million of 6.000% senior unsecured notes due 2034 at 100% of face value, with closing expected on March 5, 2026. The company plans to use the net proceeds to tender for its $500 million of 6.875% senior notes due 2028 and to repay borrowings under its credit facility, which changes the mix of its debt rather than announcing a new operating result.
Offering: $750 million of 6.000% senior unsecured notes due 2034, priced at 100% of face value on February 26, 2026
Expected closing: March 5, 2026, subject to customary closing conditions
Use of proceeds: cash tender offer for the $500 million outstanding 6.875% senior notes due 2028, plus repayment of credit facility borrowings
NW Natural Holdings reported full-year 2025 GAAP EPS of $2.77, up from $2.03, and adjusted EPS of $2.93, up from $2.33. For the fourth quarter, GAAP EPS rose to $1.39 from $1.12, while adjusted EPS was $1.39 versus $1.41 a year earlier. The company set 2026 EPS guidance of $2.95–3.15 and announced the MX3 Mist gas storage expansion, which is expected to cost about $300 million.
Full-year 2025 GAAP net income was $113.3 million ($2.77 per share), up from $78.9 million ($2.03 per share) in 2024.
Fourth-quarter 2025 GAAP net income was $57.8 million ($1.39 per share), up from $45.0 million ($1.12 per share); adjusted EPS was $1.39 versus $1.41.
2026 EPS guidance is $2.95–3.15; the company targets 4.0–6.0% long-term EPS growth through 2030.
MX3 storage expansion is expected to cost about $300 million and be in service by the end of 2029; the company declared a quarterly dividend of $0.4925 per share.
Tanger entered a new at-the-market equity program with a maximum gross sales price of $400 million, replacing its February 24, 2025 sales agreement, which it terminated without having issued any shares. The company may sell shares from time to time at its discretion and has no obligation to sell, so the program's dilutive effect depends on future sales that the filing does not quantify.
Maximum aggregate gross sales price under the 2026 Sales Agreement is $400 million.
Sales agents include BofA Securities, Wells Fargo Securities, BTIG, Mizuho, Nomura, Regions, Scotia Capital, TD Securities, and Truist Securities, among others.
Compensation to each sales agent will not exceed 2.0% of gross sales price of issuance shares sold through it.
Company intends to use net proceeds for general corporate purposes, including acquisitions, development, and debt repayment; the 2025 agreement had no shares issued as of February 26, 2026.
Graphic Packaging amended its credit agreement with Bank of America, N.A., as administrative agent, raising the maximum Consolidated Total Leverage Ratio. The company said it requested the change because its decision to aggressively reduce inventory depresses EBITDA and increases the ratio. For shareholders, the amendment loosens debt limits while capping share repurchases at $65 million a year and adding restrictions on acquisitions and investments during the Specified Period.
Maximum leverage ratio rises from 4.25 to 1.00 to 5.00 to 1.00 for quarters ending March 31, 2026 through December 31, 2026, and to 4.75 to 1.00 for quarters ending March 31, 2027 through June 30, 2027
Share repurchases are limited to $65 million on an annual basis during the Specified Period, which ends when quarterly financial statements for the quarter ending September 30, 2027 are delivered
An additional pricing tier applies when the leverage ratio is at or above 4.75 to 1.00, and acquisitions and investments in non-guarantor subsidiaries face added restrictions
On February 24, 2026, Macerich's operating partnership, The Macerich Partnership, L.P., entered a Second Amended and Restated Credit Agreement that provides a $900 million revolving loan facility. The agreement replaces a credit agreement dated September 11, 2023, and lets the borrower increase the facility up to $1.1 billion, subject to lender commitments and other conditions. The facility is secured by mortgages and equity pledges and includes a borrowing base covenant and financial covenants.
Revolving loan facility of $900 million, maturing March 1, 2029, with an option to extend to March 1, 2030.
Facility can be increased to an aggregate $1.1 billion, subject to lender commitments and other conditions.
At signing, the applicable margin was 0.90% for Base Rate loans and 1.90% for Term SOFR loans.
Secured by mortgages on certain wholly-owned assets and pledges of certain equity interests; requires a Borrowing Base Maintenance Covenant.
CNX Resources Corporation completed a private offering of $500 million in 5.875% senior notes due March 1, 2034, on February 26, 2026. The company said it intends to use the net proceeds to tender for and, if needed, redeem its outstanding 6.000% senior notes due 2029, with any shortfall funded from its revolving credit facility, so the deal mainly refinances existing debt.
$500 million aggregate principal of 5.875% senior notes due March 1, 2034, issued under an indenture with UMB Bank, N.A., as trustee
Interest is payable semi-annually on March 1 and September 1, beginning September 1, 2026
Proceeds intended to fund a tender offer for, and if needed the redemption of, the company's 6.000% senior notes due 2029
Notes are redeemable on or after March 1, 2029 at 102.938% of principal, declining to 100% in 2031 and thereafter
Vir Biotechnology entered into an underwriting agreement on February 25, 2026, to sell 17,647,059 shares of common stock at $8.50 per share. The company expects net proceeds of about $141.1 million, or about $162.3 million if underwriters fully exercise their option for additional shares, but the sale adds new shares outstanding, which dilutes existing shareholders.
Offering of 17,647,059 common shares at $8.50 per share, with underwriters led by Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc.
Expected net proceeds of approximately $141.1 million, or approximately $162.3 million if the underwriters' option is fully exercised.
Underwriters hold a 30-day option to buy up to 2,647,058 additional shares at the public offering price.
Offering is expected to close on February 27, 2026, subject to customary closing conditions.
Dr. Julian Kenyon retired from the Board of Directors of Propanc Biopharma, Inc. effective February 20, 2026, to focus on his personal and family life, and will remain a medical advisor to the company. The same day, the Board filled the vacancy by appointing Dr. Ralf Brant, a pharmaceutical and oncology research executive, to serve until his removal or resignation.
Dr. Julian Kenyon retired and stepped down from the Board effective February 20, 2026, and will remain a medical advisor to the company.
Dr. Ralf Brant was appointed to the Board on February 20, 2026, to fill the vacancy.
The filing describes Dr. Brant as having over thirty years of experience in drug discovery and oncology, and as a serving member of scientific advisory boards including Propanc Biopharma.
Exhibit 10.1, a Director Agreement dated February 20, 2026, is filed with the report; the exhibit names the director as Dr. Ralf Brandt.
AbbVie agreed on February 24, 2026 to sell seven series of senior notes, with total principal of $8.0 billion, to a group of underwriters led by J.P. Morgan, BofA Securities, Morgan Stanley and Wells Fargo. The company expects net proceeds of about $7.95 billion, which it plans to use mainly to repay amounts outstanding under a $4.0 billion 364-day delayed draw term loan facility maturing in May 2026, of which $2.0 billion is currently outstanding.
Seven series of senior notes with total principal of $8.0 billion, maturing from 2028 to 2066
Expected net proceeds of about $7.95 billion after underwriting discounts and estimated offering expenses
Proceeds planned to repay the $4.0 billion 364-day term loan, of which $2.0 billion is outstanding, and for general corporate purposes
Closing expected March 4, 2026, subject to customary closing conditions
On February 26, 2026, Boston Scientific entered three new credit agreements with Wells Fargo as administrative agent and terminated its 2021 revolving credit agreement. The $6.000 billion term loan may be drawn only to fund the pending acquisition of Penumbra, Inc., under a merger agreement dated January 14, 2026, which means the company will take on substantial new debt if the deal closes.
$3.000 billion 2026 Revolving Credit Agreement matures February 26, 2031, with a Maximum Leverage Ratio of 3.75x
$2.000 billion 364-day revolving credit agreement, with a ticking fee accruing 120 days after its effective date
$6.000 billion term loan: $1.000 billion Tranche A and $5.000 billion Tranche B, drawable only at the Penumbra acquisition closing
Prior 2021 revolving credit agreement, as amended through May 10, 2024, was terminated
CenterPoint Energy completed the sale of $650 million of 2.875% Convertible Senior Notes due 2029, including the full $50 million option, with net proceeds of about $641.5 million after discounts and expenses. The notes are senior unsecured debt that can convert into cash, common stock, or both, and the initial conversion price of about $53.61 per share is a 25.0% premium over the February 23, 2026 closing price, so the deal adds debt while creating potential future share dilution of up to 15,155,010 shares.
Aggregate principal of $650 million, including an additional $50 million from the initial purchasers' option, sold in a private offering under Rule 144A.
Notes bear 2.875% interest, payable May 15 and November 15 starting November 15, 2026, and mature May 15, 2029.
Initial conversion price of about $53.61 per share; a maximum of 15,155,010 shares may be issued on conversion.
Indenture is dated February 26, 2026, with The Bank of New York Mellon Trust Company, National Association, as trustee.
NewMarket Corporation's board elected Bruce R. Hazelgrove, III, the company's Executive Vice President and Chief Administrative Officer, as a director on February 26, 2026, effective immediately. He will not receive extra compensation for board service and will sit on the Executive Committee, but not on other board committees because he is not independent as a company officer.
Board election effective February 26, 2026; Hazelgrove is currently Executive Vice President and Chief Administrative Officer
No additional compensation for his board service
Will serve on the Executive Committee; not independent, so no other board committees
Related-party information is incorporated by reference from the March 12, 2025 proxy statement
Arlo Technologies reported fourth-quarter and full-year 2025 results on February 26, 2026, with Q4 revenue of $141.3 million, up from $121.6 million a year earlier, and a GAAP profit of $0.05 per share compared with a loss of $0.05. The company also gave first-quarter 2026 revenue guidance of $135 million to $145 million and non-GAAP EPS guidance of $0.17 to $0.23, and said it has a partnership with Comcast for connected home security.
Q4 2025 revenue of $141.3 million, versus $121.6 million in Q4 2024
Q4 2025 GAAP EPS of $0.05 versus a loss of $0.05 in Q4 2024; full-year GAAP EPS of $0.14 versus a loss of $0.31 in 2024
Full-year 2025 revenue of $529.3 million, versus $510.9 million in 2024
Q1 2026 guidance: GAAP revenue of $135 million to $145 million; non-GAAP diluted EPS of $0.17 to $0.23
Concentra reported fourth-quarter 2025 revenue of $539.1 million, up 15.9%, and net income attributable to the Company of $34.7 million, up 61.2%. For full-year 2025, revenue rose 13.9% to $2,163.4 million, while net income attributable to the Company was flat at $166.4 million and EPS fell to $1.30 from $1.46. The company also gave 2026 guidance of $2.25 billion to $2.35 billion in revenue and declared a $0.0625 per share dividend.
Q4 2025 EPS was $0.27 versus $0.17 in Q4 2024; Adjusted EBITDA was $95.3 million, up 22.9%.
Full-year 2025 EPS was $1.30 versus $1.46 in 2024; full-year net income attributable to the Company was $166.4 million, down 0.1%.
2026 guidance: revenue of $2.25 billion to $2.35 billion and Adjusted EBITDA of $450 million to $470 million.
Board declared a $0.0625 per share dividend, payable on or about March 19, 2026, to holders of record on March 12, 2026.
Federal Signal's board increased its size from seven to nine directors and appointed Richard A. Maue, CFO of Crane Company, and Eric A. Vaillancourt, CEO of Enpro Inc., effective February 26, 2026. The filing describes the appointments as board additions with standard director compensation and no financial results, so they carry no direct financial figures for shareholders.
Board expanded from seven to nine directors on February 26, 2026.
Richard A. Maue joins the Audit Committee; he has been CFO of Crane Company since January 2013.
Eric A. Vaillancourt joins the Compensation and Benefits Committee; he has been CEO of Enpro Inc. since November 28, 2021.
Each new director receives a $90,000 annual base retainer and a $145,000 annual equity award beginning in 2026.
On February 25, 2026, CBRE's Compensation Committee issued a one-time retention award with a $5.0 million total target grant value to Vikram Kohli, the company's Chief Operating Officer and Chief Executive Officer, Advisory Services. The award consists entirely of performance RSUs that vest only if relative TSR or relative EPS goals are met over five-year periods, and it is also contingent on Kohli remaining employed for the full five-year vesting period.
Total target grant value of $5.0 million, split equally between relative TSR and relative EPS performance RSUs
Payouts range from 0% to 175% of target, with no vesting unless performance exceeds the 40th percentile of S&P 500 companies as of February 25, 2026
rTSR measurement period runs from February 25, 2026 to January 31, 2031; rEPS period runs from January 1, 2026 to December 31, 2030
Vesting term of five years is longer than the three-year vesting period for CBRE's annual Performance RSU awards
AMG announced that G. Staley Cates, former Vice Chairman of Southeastern Asset Management, will join its Board as an independent director effective April 1, 2026. Director Karen L. Alvingham, who joined the Board in January 2018, will retire from the Board on the same date, and Jay C. Horgen was re-appointed President effective April 1, 2026 while continuing as Chief Executive Officer. The filing contains no financial results, so the changes affect board composition and leadership titles rather than reported performance.
G. Staley Cates joins the Board as an independent director effective April 1, 2026; he was Vice Chairman of Southeastern from 2015 through 2024 and its President from 1989 through 2015.
Karen L. Alvingham will retire from the Board effective April 1, 2026; she was appointed in January 2018.
Jay C. Horgen was re-appointed President effective April 1, 2026 and will continue to serve as Chief Executive Officer.
Rexford Industrial Realty appointed John Nahas as Chief Operating Officer effective April 1, 2026, alongside Laura Clark's previously announced move to Chief Executive Officer. The company also adopted an Executive Severance Plan and said it reaffirmed its 2026 general and administrative expense guidance of approximately $60 million.
Nahas, age 43, joined the company in January 2023 and has been Managing Director of Operations and Asset Management since July 2023.
The company reaffirmed its previously disclosed 2026 general and administrative expense guidance of approximately $60 million.
The press release says total aggregate executive compensation was significantly reduced by approximately 50% compared with prior levels.
The Executive Severance Plan is effective February 24, 2026; Co-CEOs Michael S. Frankel and Howard Schwimmer are excluded from it.
NCR Atleos entered into a merger agreement under which Brink's will acquire it in a cash and stock transaction valued at about $6.6 billion, including the assumption of about $2.6 billion of NCR Atleos debt. NCR Atleos shareholders would receive $30.00 in cash and 0.1574 Brink's shares per share, an implied $50.40 per share based on Brink's February 25, 2026 closing price, and the deal is expected to close in the first quarter of 2027 subject to approvals, including shareholder votes at both companies.
Consideration per NCR Atleos share: $30.00 in cash plus 0.1574 Brink's common shares, an implied $50.40 based on Brink's $129.58 close on February 25, 2026
Implied price represents a premium of about 24% over NCR Atleos' February 25, 2026 closing price and 26% over its 30-day volume weighted average price
After closing, Brink's shareholders would own about 78% and NCR Atleos shareholders about 22% of the combined company
Closing is expected in the first quarter of 2027, subject to stockholder and shareholder approvals, regulatory approvals and other conditions
Amphastar reported fourth-quarter and full-year 2025 results on February 26, 2026. Revenue, GAAP net income and diluted EPS declined from 2024 in both periods, and the release does not include financial guidance for 2026. Full-year results include a $23.1 million litigation provision, and glucagon sales fell 45% in the fourth quarter on lower average selling prices and unit volumes.
Q4 2025 net revenues were $183.1 million, down 2% from $186.5 million in Q4 2024
Q4 GAAP diluted EPS was $0.51 vs. $0.74; adjusted non-GAAP diluted EPS was $0.73 vs. $0.92
Full-year 2025 net revenues were $719.9 million vs. $732.0 million; GAAP diluted EPS was $2.03 vs. $3.06
BAQSIMI sales rose 46% to $185.4 million for the full year, while glucagon sales fell 36% to $69.1 million
Monster Beverage reported fourth-quarter and full-year 2025 results on February 26, 2026, with net sales, net income and diluted earnings per share all higher than in 2024. The company also named new regional leaders and said no shares were repurchased in the fourth quarter, leaving about $500.0 million available under its buyback program.
Q4 2025 net income rose 65.9% to $449.2 million, and diluted EPS rose to $0.46 from $0.28 a year earlier.
Full-year 2025 net sales rose 10.7% to $8.29 billion, and diluted EPS rose to $1.94 from $1.49.
Effective February 25, 2026, Rob Gehring became CEO, Americas, Guy Carling became CEO, EMEA & OSP, and Emelie Tirre became Chief Strategy Officer.
No shares were repurchased in Q4 2025; about $500.0 million remained available under the existing repurchase program as of February 26, 2026.
MARA Holdings reported preliminary, unaudited results for the fourth quarter and full year 2025, showing revenue down 6% in the quarter and a net loss of $1.7 billion, compared with net income of $528.3 million a year earlier. The company attributed the swing mainly to a $1.5 billion loss on fair value of digital assets as bitcoin prices fell, and it also announced a joint venture with Starwood Digital Ventures to develop AI and high-performance compute infrastructure. Final figures will come in the Form 10-K, so the reported numbers could change.
Q4 2025 revenue fell 6% to $202.3 million from $214.4 million in Q4 2024, driven by a 14% decrease in the average bitcoin price.
Q4 2025 net loss was $1.7 billion, or $4.52 per diluted share, versus net income of $528.3 million, or $1.24 per diluted share, in Q4 2024.
Full-year 2025 revenue rose 38% to $907.1 million, while the full-year net loss was $1.3 billion compared with net income of $541.0 million in 2024.
Adjusted EBITDA was a loss of $1.5 billion in Q4 2025 versus $796.0 million in Q4 2024; results remain preliminary and unaudited.
MasTec reported fourth quarter 2025 revenue of $3.9 billion, up 16% year over year, and GAAP diluted EPS of $1.81 versus $0.95 a year earlier. The company also issued initial guidance for 2026 of $17.0 billion in revenue and $8.40 in adjusted diluted EPS, compared with $6.55 in 2025, so shareholders get a forecast of continued growth.
Q4 2025 revenue was $3.9 billion, up 15.8% from $3.4 billion; GAAP net income was $153 million versus $85 million
Full-year 2025 revenue was $14.3 billion and GAAP net income was $422 million, both up from 2024
2026 guidance: revenue of $17.0 billion and adjusted EBITDA of $1.45 billion for the full year
Q1 2026 guidance: revenue of $3.475 billion and adjusted diluted EPS of $1.00
Arcosa reported fourth-quarter 2025 net income of $52.1 million, compared with a net loss of $7.7 million a year earlier, and full-year 2025 revenue of $2.88 billion, up 12%. The company also guided to 2026 revenue of $2.95 billion to $3.10 billion and adjusted EBITDA of $590 million to $640 million, excluding its planned $450 million sale of the barge business, which is expected to close in the second quarter of 2026.
Q4 2025 net income was $52.1 million, or $1.06 diluted EPS, versus a net loss of $7.7 million, or $(0.16) per share, in Q4 2024.
Full-year 2025 revenue was $2.88 billion, up 12%, and adjusted EBITDA was $583.3 million, up 30%.
2026 guidance: revenue of $2.95 billion to $3.10 billion and adjusted EBITDA of $590 million to $640 million, excluding the barge divestiture.
Barge business (Arcosa Marine Products) to be sold to Wynnchurch Capital L.P. for $450 million in cash, expected to close in Q2 2026; Group President Jesse E. Collins Jr. retires effective April 3, 2026.
Assured Guaranty reported fourth quarter 2025 net income attributable to the company of $119 million, or $2.53 per diluted share, up from $18 million, or $0.35 per share, a year earlier. For full year 2025, net income was $503 million, or $10.26 per share, compared with $376 million, or $6.87 per share, in 2024. The company also reported that it returned $500 million to shareholders through share repurchases in 2025.
Q4 2025 adjusted operating income was $109 million, or $2.32 per share, versus $66 million, or $1.27 per share, in Q4 2024.
FY 2025 adjusted operating income was $445 million, or $9.08 per share, versus $389 million, or $7.10 per share, in FY 2024.
Q4 2025 gross written premiums were $61 million, down from $186 million in Q4 2024; FY 2025 gross written premiums were $256 million, down from $440 million.
Shareholders' equity attributable to the company was $125.32 per share as of December 31, 2025, up from $108.80 a year earlier.
American Healthcare REIT reported fourth quarter and full year 2025 results on February 26, 2026, showing a swing to net income from prior-year losses and higher Normalized FFO per diluted share. The company also issued 2026 guidance for Normalized FFO of $1.99 to $2.05 per diluted share, with a $2.02 midpoint, compared with $1.72 in 2025. The guidance does not assume any transactions or capital markets activity beyond those already completed.
Q4 2025 GAAP net income attributable to controlling interest was $10.8 million, or $0.06 per diluted share, versus a loss of $31.8 million, or $0.21 per share, in Q4 2024.
Full-year 2025 GAAP net income attributable to controlling interest was $69.8 million, or $0.42 per diluted share, versus a loss of $37.8 million, or $0.29 per share, in 2024.
Normalized FFO was $0.46 per diluted share in Q4 2025 versus $0.40 a year earlier, and $1.72 for 2025 versus $1.41 in 2024; total portfolio same-store NOI grew 11.8% in Q4 and 14.2% for the year.
2026 guidance calls for net income of $0.75 to $0.81 per diluted share and total portfolio same-store NOI growth of 7.0% to 11.0%.
MARA USA Corporation, a MARA subsidiary, entered into a Strategic Agreement with Starwood Capital Group on February 26, 2026. The agreement covers developing, leasing and marketing MARA's existing US bitcoin mining data center properties, outside existing third-party joint ventures, with each property potentially moving into a joint venture where MARA would hold 10% to 50%. The filing gives no dollar value for the deal, and shareholders will depend on how many properties proceed to development.
Covers all of MARA's United States bitcoin mining data center properties other than those held in existing third-party joint ventures.
MARA would elect a 10% to 50% interest in each joint venture; Starwood would be managing member and handle day-to-day operations.
Each party can decide whether to proceed after a trigger, such as an executable hyperscaler lease; a decision is required 24 months after closing, extendable by 12 months.
If Starwood proceeds and MARA does not after a qualifying lease, MARA must sell its rights to the powered land to Starwood.
Tutor Perini reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1 to a Form 8-K dated February 26, 2026. Full-year revenue rose 28% to $5.5 billion, and the company returned to a profit after a loss in 2024, with diluted EPS of $1.51 compared with a loss of $3.13. The company also gave 2026 adjusted EPS guidance of $4.90 to $5.30, which excludes share-based compensation expense.
2025 revenue was $5.5 billion, up 28% from 2024.
Income from construction operations was $232.0 million in 2025, compared with a loss of $103.8 million in 2024.
Operating cash flow was a record $748.1 million in 2025, up 49% year-over-year.
The company expects 2026 adjusted EPS of $4.90 to $5.30 and does not provide GAAP EPS guidance.
J.M. Smucker's board increased its size to 11 members and elected Woo-Sung (Bruce) Chung, CFO of NRG Energy, and David Singer, former CEO of Snyder's-Lance, effective April 15, 2026. The appointments follow engagement with Elliott Investment Management, and the company has entered an information-sharing agreement with Elliott. The filing reports no financial results, so the change is a governance development rather than a direct financial measure.
Board expanded to 11 directors, with 10 described as independent, effective April 15, 2026
Chung and Singer will both serve on the Audit Committee; Mercedes Abramo moves from Audit to Nominating, Governance, and Corporate Responsibility Committee
Appointments follow constructive engagement with Elliott Investment Management, which the company describes as one of its largest investors
Company will enter indemnity agreements with Chung and Singer, in substantially the same form as those with current directors
SBA Communications reported fourth-quarter 2025 results, with net income of $370.4 million ($3.47 per diluted share) versus $178.8 million a year earlier, though that figure includes a $226.3 million gain on the sale of its Canadian operations. AFFO per share fell 8.1% to $3.19, and the company issued initial 2026 guidance that excludes all contracted EchoStar revenue while declaring a dividend of $1.25 per share, up about 13%.
Q4 2025 site leasing revenue rose 3.1% to $666.2 million; net income was $370.4 million, or $3.47 per diluted share, versus $1.61 a year earlier.
AFFO fell 9.2% to $340.4 million, and AFFO per share fell 8.1% to $3.19 from $3.47.
2026 outlook projects total revenues of $2,815.0 million to $2,860.0 million and AFFO per share of $11.84 to $12.29, excluding all contracted EchoStar revenue.
Quarterly dividend of $1.25 per share is payable March 27, 2026, to holders of record on March 13, 2026.
Abbott agreed under a pricing agreement dated February 23, 2026, to sell $20 billion of senior notes in several series maturing from 2029 to 2066. The company said it will use the proceeds, with cash on hand and possibly additional borrowings, to pay the consideration for its acquisition of Exact Sciences, repay certain Exact Sciences debt, cover fees and expenses, and for general corporate purposes. Closing of the sale is expected on March 9, 2026, subject to customary conditions.
Total offering of $20 billion across eight series, including $1 billion of floating rate notes due 2029 and $3.75 billion each of 4.650% notes due 2036 and 5.500% notes due 2056
Proceeds intended to fund the Exact Sciences acquisition consideration and repay certain Exact Sciences indebtedness
Closing expected March 9, 2026, subject to customary closing conditions
Teledyne entered into a First Amendment to its Second Amended and Restated Credit Agreement on February 25, 2026, with Bank of America, N.A. as administrative agent. The amendment removes the Secured Overnight Financing Rate (SOFR) adjustment feature, which the original agreement set at 0.10% (ten basis points). The filing is a administrative change to loan terms and does not report any new borrowing amounts or financial results.
Amendment dated February 25, 2026, to the credit agreement originally dated June 10, 2024
Eliminates the SOFR adjustment feature, which was 0.10% (ten basis points) in the original agreement
Bank of America, N.A. serves as administrative agent, swing line lender and L/C issuer
DoubleVerify reported fourth-quarter and full-year 2025 results, with full-year revenue up 14% to $748.3 million but net income down to $50.7 million from $56.2 million in 2024. The Board also approved a $300 million share repurchase program that replaces the November 2024 program, and the company guided 2026 revenue growth of 8% to 10%.
Full-year 2025 revenue of $748.3 million, up 14%; net income of $50.7 million versus $56.2 million in 2024, and diluted EPS of $0.30 versus $0.32.
Fourth-quarter 2025 revenue of $205.6 million, up 8%, with net income of $29.3 million.
2026 guidance: full-year revenue of $810 million to $826 million, up 8% to 10%, and adjusted EBITDA margin of about 34%.
Board approved a $300 million repurchase program, replacing the November 2024 program; it has no time limit and does not obligate the company to buy a specific number of shares.
Dexcom's board increased its size to twelve directors and appointed Albert F. ("Rick") Osterloh IV, Senior Vice President, Platforms & Devices at Google, as a director effective February 26, 2026. He joins the Compensation and Technology Committees, and the filing describes him as independent under Nasdaq listing standards.
Osterloh's term expires at the 2026 annual stockholder meeting.
Initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years.
Expected annual director equity grant of restricted stock units with a fair value of $101,027, prorated from a $325,000 base award.
Itron entered into a purchase agreement to sell $700.0 million of 0.00% convertible senior notes due March 15, 2032 in a private offering, and the initial purchasers exercised in full an option for an additional $105.0 million on February 24, 2026. The notes have an initial conversion price of about $123.77 per share, a premium of about 30.0% over the $95.21 closing price on February 23, 2026, and the company paid about $92.8 million for capped call transactions meant to reduce dilution. Shareholders face possible dilution if the notes convert, though the capped calls offset some of that exposure up to a cap price of $190.42 per share.
Principal: $700.0 million initial notes plus $105.0 million option exercised in full on February 24, 2026; the notes pay no regular interest.
Initial conversion price of about $123.77 per share, a 30.0% premium to the $95.21 closing price on February 23, 2026.
Capped call transactions cost about $92.8 million, with a cap price of $190.42 per share.
Company expects to use net proceeds to pay for the capped calls, repurchase about $100.0 million of common stock, and repay its 0.00% convertible notes due 2026.
Brink's agreed to acquire NCR Atleos in a transaction valued at approximately $6.6 billion, combining cash, Brink's stock and assumed debt. The deal requires approval from shareholders of both companies and customary regulatory clearances, and is expected to close in the first quarter of 2027, so shareholders face a large acquisition with significant new debt and dilution.
Each NCR Atleos share would receive $30.00 in cash and 0.1574 Brink's shares, an implied $50.40 per share based on Brink's February 25, 2026 closing price of $129.58.
Deal value is approximately $6.6 billion, including 13.3 million Brink's shares, $2.2 billion in cash and assumption of about $2.6 billion of NCR Atleos debt.
Post-closing, Brink's shareholders would own about 78% and NCR Atleos shareholders about 22% of Brink's common stock.
Brink's has obtained $4.5 billion in committed bridge financing from Morgan Stanley Senior Funding; closing is expected in the first quarter of 2027.
Dentsply Sirona reported a fourth quarter and full-year 2025 net loss, with fourth-quarter net sales up 6.2% but full-year net sales down 3.0%. The company also eliminated its quarterly dividend, announced a restructuring plan, and set 2026 net sales and adjusted EPS outlooks below its 2025 adjusted EPS of $1.60, which matters to shareholders because the dividend is gone and the outlook implies lower per-share earnings.
Q4 2025 net sales were $961 million, up 6.2%, but the company posted a net loss of $146 million, or $0.74 per diluted share, driven by $144 million in net-of-tax goodwill and intangible impairments.
FY 2025 net sales were $3,680 million, down 3.0%, and the net loss was $598 million, or $3.00 per diluted share, compared with a $910 million loss in 2024.
FY 2026 outlook: net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50, versus FY 2025 adjusted EPS of $1.60.
The Board eliminated the quarterly cash dividend, which the company said will redirect capital to debt retirement and share repurchases; a restructuring plan carries $55 million to $65 million in charges and about $120 million in annualized
National Health Investors reported fourth quarter 2025 results and introduced 2026 annual guidance. Diluted earnings per share fell to $0.80 from $0.95 a year earlier, while normalized FFO per diluted share rose to $1.22 from $1.12, and the company projects 2026 normalized FFO per diluted share of $4.94 to $4.99.
Q4 2025 diluted EPS was $0.80 versus $0.95 in Q4 2024; NAREIT FFO per diluted share was $1.22 versus $1.24.
Full-year 2025 normalized FFO per diluted share was $4.91 versus $4.44 in 2024; diluted EPS was $3.02 versus $3.13.
2026 guidance: normalized FFO per diluted share of $4.94 to $4.99 and normalized FAD of $248.9 million to $251.4 million.
As of December 31, 2025, net debt was $1.2 billion and net debt to adjusted EBITDA was 3.8x.
PPL Corporation completed an offering of 23,000,000 equity units on February 26, 2026, including the full exercise of the underwriters' over-allotment option. Each unit has a $50 stated amount and combines a stock purchase contract with a beneficial interest in remarketable senior notes issued by PPL Capital Funding, Inc. and guaranteed by PPL, so the offering can add future common stock issuance for holders who settle the contracts.
Offering covered 20,000,000 units plus 3,000,000 over-allotment units, for 23,000,000 units in total, completed February 26, 2026.
Each unit has a $50 stated amount and total annual distributions of 7.00%, made up of 2.98% contract adjustment payments and 4.02% note interest.
Stock purchase contracts require holders to buy common stock for $50 in cash no later than February 15, 2029.
Underwriters for the offering were J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC.
NCR Atleos reported fourth quarter and full year 2025 results alongside an agreement to be acquired by The Brink's Company in a cash and stock transaction. Results improved, with 2025 revenue up 1% to $4.35 billion and net income attributable to Atleos up 103% to $162 million, but the company will not issue 2026 guidance and has suspended its share repurchase program.
Definitive agreement to be acquired by The Brink's Company in a cash and stock transaction, announced February 26, 2026.
2025 revenue of $4.35 billion, up 1%; diluted EPS of $2.14, up 98%; adjusted diluted EPS of $4.13, up 24%.
Operating cash flow of $356 million for 2025, up 35%; 1.2 million shares repurchased for $44 million through February 2026.
No 2026 financial guidance will be issued, the share repurchase program is suspended, and the February 27, 2026 earnings call was cancelled.
On February 26, 2026, Phillips Edison Grocery Center Operating Partnership I, L.P., a subsidiary, completed an underwritten public offering of $350 million of 4.750% senior notes due March 15, 2033, fully guaranteed by parent Phillips Edison & Company, Inc. The notes were sold at 99.295% of principal, with estimated net proceeds of about $346.5 million, which the company intends to use for general corporate purposes, including repaying its revolving credit facility and term loans.
$350 million principal of 4.750% senior notes, maturing March 15, 2033; interest is payable March 15 and September 15, starting September 15, 2026.
Underwriters paid 99.295% of principal; estimated net proceeds are about $346.5 million after the underwriting discount and fees.
Proceeds are intended for general corporate purposes, including repaying revolver borrowings and term loans.
The issuer may redeem the notes before January 15, 2033 at the greater of par or a make-whole premium, and at par afterward.
On February 26, 2026, NextEra Energy Capital Holdings, a wholly-owned subsidiary of NextEra Energy, sold €1.0 billion of Series X and €750 million of Series Y junior subordinated debentures maturing in 2056. The debt is guaranteed on a subordinated basis by NextEra Energy, so it adds long-term borrowing that ranks behind other obligations and is tied to the parent's credit.
Series X: €1.0 billion principal, 4.20% fixed rate until February 26, 2032, then resets to the Five-Year Swap Rate plus a margin
Series Y: €750 million principal, 4.75% fixed rate until February 26, 2036, then resets on the same five-year cycle
NEECH may redeem Series X debentures beginning in 2031 and Series Y debentures beginning in 2035
Debentures were registered under Securities Act Registration Statement Nos. 333-278184 and related numbers
Rocket Lab reported fourth-quarter 2025 revenue of $179.7 million, up from $132.4 million a year earlier, and full-year revenue of $601.8 million, up from $436.2 million. The company also guided to first-quarter 2026 revenue of $185 million to $200 million, but its net loss widened for the full year to $198.2 million from $190.2 million.
Q4 2025 revenue $179.7 million vs $132.4 million in Q4 2024; net loss $52.9 million, or $0.09 per share, vs $52.3 million, or $0.10 per share
Full-year 2025 revenue $601.8 million vs $436.2 million in 2024; net loss $198.2 million, or $0.37 per share
Q1 2026 guidance: revenue $185 million to $200 million; adjusted EBITDA loss $21 million to $27 million
Backlog reached $1.85 billion at year-end, up 73% year on year; Neutron first launch now targeted for Q4 2026
Dell reported record fiscal 2026 fourth-quarter revenue of $33.4 billion, up 39%, and record full-year revenue of $113.5 billion, up 19%. It guided fiscal 2027 revenue to $138.0 billion to $142.0 billion, and it raised its cash dividend by 20% and its share repurchase authorization by $10 billion.
Q4 FY26 revenue of $33.4 billion, up 39%; diluted EPS of $3.37, up 57%
FY26 revenue of $113.5 billion, up 19%; diluted EPS of $8.68, up 36%
FY27 revenue guidance of $138.0 billion to $142.0 billion; GAAP diluted EPS midpoint of $11.52
Strategic Education reported fourth quarter 2025 revenue of $323.2 million, up 3.8%, and diluted earnings per share of $1.66 compared with $1.05 a year earlier. For full-year 2025, revenue rose 4.0% to $1,268.2 million and diluted EPS was $5.41 versus $4.67, with the company also declaring a $0.60 quarterly dividend for shareholders of record as of March 9, 2026.
Q4 2025 income from operations was $51.6 million, or 16.0% of revenue, versus $36.0 million, or 11.6%, in Q4 2024
Full-year 2025 net income was $126.6 million, compared with $112.7 million in 2024, and the company repurchased shares for $138.9 million during the year
Quarterly cash dividend of $0.60 per share, payable March 16, 2026
The filing does not include financial guidance for 2026
Brink's reported fourth-quarter 2025 revenue of $1,379 million, up 9% (5% organic), and GAAP earnings per share of $1.62, up 93%. For full-year 2025, revenue reached $5,261 million (up 5%) and GAAP EPS was $4.70 (up 30%), and the company gave first-quarter 2026 non-GAAP guidance and a 2026 framework.
Q4 2025 operating profit was $180 million on a GAAP basis, up 72%, and non-GAAP EPS was $2.54, up 20%.
Full-year 2025 adjusted EBITDA was $977 million, up 7%, with operating cash flow of $640 million and free cash flow of $436 million.
Q1 2026 non-GAAP guidance calls for revenue of $1,335 million to $1,395 million, adjusted EBITDA of $220 million to $240 million, and EPS of $1.50 to $1.90.
Net debt leverage fell to 2.7 times adjusted EBITDA, and the company returned over $250 million to shareholders through dividends and share repurchases.
Fox Factory reported fourth-quarter fiscal 2025 net sales of $361.1 million, up 2.3%, but posted a net loss of $287.0 million, or $6.86 per diluted share, driven mainly by goodwill impairment. Adjusted EBITDA fell to $35.0 million from $40.4 million, and the company launched a Phase 2 profit plan and introduced fiscal 2026 guidance for adjusted EBITDA of $174 million to $203 million.
Q4 net sales rose 2.3% to $361.1 million; net loss was $287.0 million, or $6.86 per diluted share, versus a $0.1 million loss a year earlier.
Adjusted EPS was $0.20 versus $0.31 in the prior-year quarter; adjusted EBITDA was $35.0 million versus $40.4 million.
Full-year fiscal 2025 goodwill impairment was $557.3 million; goodwill fell to $83.6 million from $639.5 million.
Phase 2 targets about $40 million in additional savings in 2026; fiscal 2026 net sales guidance is $1.328 billion to $1.416 billion, and the company expects to divest its Phoenix, Arizona AAG operations by the end of Q1 fiscal 2026.
Solventum reported fourth-quarter 2025 net sales of $1,998 million, down 3.7% on a reported basis but up 3.5% organically, and introduced 2026 full-year guidance. Adjusted diluted EPS rose to $1.57 from $1.41, while the company guided to 2026 adjusted EPS of $6.40 to $6.60, compared with $6.11 for full-year 2025.
Q4 2025 reported net sales of $1,998 million, down 3.7%; organic sales up 3.5%
Q4 2025 GAAP diluted EPS of $0.36 versus $0.17; adjusted diluted EPS of $1.57 versus $1.41
2026 guidance: organic sales growth of 2.0% to 3.0%, adjusted EPS of $6.40 to $6.60, and free cash flow of about $200 million
Full-year 2025 free cash flow was negative $10 million and adjusted EPS was $6.11, down 8.8%
Sunrun reported fourth-quarter 2025 revenue of $1,158.8 million, up 124% from a year earlier, and net income attributable to common stockholders of $103.6 million, compared with a loss of $2.81 billion a year earlier that included a $3.1 billion goodwill impairment. However, the company's Contracted Net Value Creation fell 44% to $176 million, and it gave full-year 2026 guidance for Contracted Net Value Creation of $650 million to $1.05 billion and Cash Generation of $250 million to $450 million.
Q4 2025 total revenue was $1,158.8 million, up $640.3 million, or 124%, driven partly by a third-quarter 2025 transaction in which certain systems were sold to a third party.
Q4 2025 net income attributable to common stockholders was $103.6 million ($0.38 per diluted share), versus a loss of $2,813.7 million in Q4 2024.
Contracted Net Value Creation was $176 million in Q4 2025, down 44%, and Subscriber Additions were 25,475, down 17%.
For full-year 2026, Sunrun expects Aggregate Subscriber Value of $4.8 billion to $5.2 billion and Contracted Net Value Creation of $650 million to $1.05 billion.
BioLife Solutions reported fourth quarter and full year 2025 results and introduced 2026 guidance of $112.5 million to $115.0 million in revenue, up 17% to 20%. Revenue grew in both periods and the company returned to a quarterly net profit from continuing operations, but the full-year loss from continuing operations widened to $12.1 million from $8.8 million, including a $15.5 million in-process R&D expense.
Q4 2025 revenue from continuing operations was $24.8 million, up 20% from $20.7 million; full-year revenue was $96.2 million, up 29%.
Q4 2025 GAAP net income from continuing operations was $2.1 million, or $0.04 per share, compared with a $1.2 million loss in Q4 2024.
Full-year 2025 GAAP net loss from continuing operations was $12.1 million, compared with $8.8 million in 2024; adjusted EBITDA was $25.0 million, or 26% of revenue.
The company completed the sale of evo on October 6, 2025, for $25.5 million in cash; cash, equivalents and marketable securities were $120.2 million at December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.